WASHINGTON, DC--Officials at the U.S. Food and Drug Administration (FDA, Rockville, MD) recently drew scornful reactions from industry when they aired their version of tough new financial disclosure rules for clinical investigators, rules intended tokeep bias from tainting cli nical trials in which FDA-regulated products are being evaluated. Conceivably, FDA officials could discard results from clinical trials in which such financial conflicts of interest had not been duly repotted. This possibil ity alarms moderates, including those who otherwise sympathize with FDA's efforts to set high ethical standards for clinical investigators The furor may grow worse if FDA officials succeed in broadening the proposed rules to cover other industry sectors, namely, veterinary drugs, as well as human and animal foods.
展开▼
